tiprankstipranks
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
US Market
RNAC
Cartesian Therapeutics
RESEARCH TOOLSreports
Want to see RNAC full AI Analyst Report?

Cartesian Therapeutics (RNAC) Stock Forecast & Price Target

1,168 Followers
See the Price Targets and Ratings of:

RNAC Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Cartesian
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RNAC Stock 12 Month Forecast

Average Price Target

$31.80
▲(351.70% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Cartesian Therapeutics in the last 3 months. The average price target is $31.80 with a high forecast of $40.00 and a low forecast of $16.00. The average price target represents a 351.70% change from the last price of $7.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.92,9.464615384615385,12.009230769230768,14.553846153846152,17.098461538461535,19.64307692307692,22.187692307692306,24.732307692307693,27.276923076923076,29.82153846153846,32.36615384615384,34.910769230769226,37.45538461538461,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.92,8.833846153846153,10.747692307692308,12.661538461538463,14.575384615384616,16.489230769230772,18.403076923076924,20.316923076923075,22.230769230769234,24.144615384615385,26.058461538461543,27.972307692307695,29.886153846153846,{"y":31.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.92,7.618461538461538,8.316923076923077,9.015384615384615,9.713846153846154,10.412307692307692,11.11076923076923,11.80923076923077,12.507692307692308,13.206153846153846,13.904615384615385,14.603076923076923,15.301538461538462,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$31.80Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on RNAC
Gil Blum
Needham
Needham
$40
Buy
468.18%
Upside
Reiterated
06/09/26
From: , Tuesday, June 9, 2026 1:42 PM 2026 COMPANY FLASH Biotechnology Cartesian Therapeutics, Inc. (RNAC) RATING BUY PRICE TARGET $40.00 PREV CLOSE $5.86 52-WEEK RANGE $5.60 - $15.57 The licensing agreement provides Cartesian access to WestGene's targeted LNP platform. The company initially plans to evaluate the same anti-BCMA CAR mRNA payload currently used in Descartes-08, while retaining the flexibility to advance internally developed next- generation anti-BCMA CAR and TCE constructs into future clinical programs. A China- based Phase I dose-escalation study in patients with generalized myasthenia gravis (gMG) is expected to commence in 2H:26, with initial clinical data anticipated in 1H:27.
Mizuho Securities Analyst forecast on RNAC
Uy Ear
Mizuho Securities
Mizuho Securities
$40
Buy
468.18%
Upside
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Cartesian Therapeutics (NASDAQ: RNAC) and Abbott Laboratories (NYSE: ABT)
Leerink Partners Analyst forecast on RNAC
Thomas Smith
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on RNAC
Martin Fan
Wedbush
Wedbush
$38
Buy
439.77%
Upside
Reiterated
05/27/26
Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)
H.C. Wainwright Analyst forecast on RNAC
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
255.11%
Upside
Reiterated
05/26/26
H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
TD Cowen Analyst forecast on RNAC
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on RNAC
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$16
Buy
127.27%
Upside
Reiterated
04/30/26
Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
BTIG Analyst forecast on RNAC
Julian Harrison
BTIG
BTIG
$42→$44
Buy
525.00%
Upside
Reiterated
11/14/25
Analysts Offer Insights on Healthcare Companies: Athira Pharma (NASDAQ: ATHA) and Cartesian Therapeutics (NASDAQ: RNAC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on RNAC
Gil Blum
Needham
Needham
$40
Buy
468.18%
Upside
Reiterated
06/09/26
From: , Tuesday, June 9, 2026 1:42 PM 2026 COMPANY FLASH Biotechnology Cartesian Therapeutics, Inc. (RNAC) RATING BUY PRICE TARGET $40.00 PREV CLOSE $5.86 52-WEEK RANGE $5.60 - $15.57 The licensing agreement provides Cartesian access to WestGene's targeted LNP platform. The company initially plans to evaluate the same anti-BCMA CAR mRNA payload currently used in Descartes-08, while retaining the flexibility to advance internally developed next- generation anti-BCMA CAR and TCE constructs into future clinical programs. A China- based Phase I dose-escalation study in patients with generalized myasthenia gravis (gMG) is expected to commence in 2H:26, with initial clinical data anticipated in 1H:27.
Mizuho Securities Analyst forecast on RNAC
Uy Ear
Mizuho Securities
Mizuho Securities
$40
Buy
468.18%
Upside
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Cartesian Therapeutics (NASDAQ: RNAC) and Abbott Laboratories (NYSE: ABT)
Leerink Partners Analyst forecast on RNAC
Thomas Smith
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on RNAC
Martin Fan
Wedbush
Wedbush
$38
Buy
439.77%
Upside
Reiterated
05/27/26
Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)
H.C. Wainwright Analyst forecast on RNAC
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
255.11%
Upside
Reiterated
05/26/26
H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
TD Cowen Analyst forecast on RNAC
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on RNAC
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$16
Buy
127.27%
Upside
Reiterated
04/30/26
Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
BTIG Analyst forecast on RNAC
Julian Harrison
BTIG
BTIG
$42→$44
Buy
525.00%
Upside
Reiterated
11/14/25
Analysts Offer Insights on Healthcare Companies: Athira Pharma (NASDAQ: ATHA) and Cartesian Therapeutics (NASDAQ: RNAC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cartesian Therapeutics

3 Months
Thomas SmithLeerink Partners
Success Rate
5/14 ratings generated profit
36%
Average Return
-9.53%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -9.53% per trade.
1 Year
Gil BlumNeedham
Success Rate
1/23 ratings generated profit
4%
Average Return
-36.16%
Copying Gil Blum's trades and holding each position for 1 Year would result in 4.35% of your transactions generating a profit, with an average return of -36.16% per trade.
2 Years
Gil BlumNeedham
Success Rate
0/23 ratings generated profit
0%
Average Return
-49.41%
Copying Gil Blum's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -49.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNAC Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
6
8
13
11
Buy
0
1
1
4
3
Hold
1
2
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
9
11
19
15
In the current month, RNAC has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RNAC average Analyst price target in the past 3 months is 31.80.
Each month's total comprises the sum of three months' worth of ratings.

RNAC Financial Forecast

RNAC Earnings Forecast

Next quarter’s earnings estimate for RNAC is -$0.88 with a range of -$1.05 to -$0.60. The previous quarter’s EPS was -$1.46. RNAC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RNAC has Performed in-line its overall industry.
Next quarter’s earnings estimate for RNAC is -$0.88 with a range of -$1.05 to -$0.60. The previous quarter’s EPS was -$1.46. RNAC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RNAC has Performed in-line its overall industry.

RNAC Sales Forecast

Next quarter’s sales forecast for RNAC is $180.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $78.00K. RNAC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RNAC has Performed in-line its overall industry.
Next quarter’s sales forecast for RNAC is $180.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $78.00K. RNAC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RNAC has Performed in-line its overall industry.

RNAC Stock Forecast FAQ

What is RNAC’s average 12-month price target, according to analysts?
Based on analyst ratings, Cartesian Therapeutics, Inc.’s 12-month average price target is 31.80.
    What is RNAC’s upside potential, based on the analysts’ average price target?
    Cartesian Therapeutics, Inc. has 351.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RNAC a Buy, Sell or Hold?
          Cartesian Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Cartesian Therapeutics, Inc.’s price target?
            The average price target for Cartesian Therapeutics, Inc. is 31.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $16.00. The average price target represents 351.70% Increase from the current price of $7.04.
              What do analysts say about Cartesian Therapeutics, Inc.?
              Cartesian Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of RNAC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.